There are no conflicts of interest for either author on this manuscript.
1. Zoorob RJ and Cender D. A different look at corticosteroids. Am Fam Phys 1998; 58(2):443–50.
2. Buttgereit F, Da Silva JAP, Boers M, et al. Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: current questions and tentative answers in rheumatology. Ann Rheum Dis 2002;61:718–22.
3.Hall BM and Hodgkinson SJ. Corticosteroids in autoimmune diseases. Aust Prescr 1999; 22:9–11.
4.van Staa TP, Leufkens HG, Abenhaim L, et al. Use of oral corticosteroids in the United Kingdom. QJM 2000;93(2):105–111.
5. Brassard P, Bitton A, Suissa A, et al. Oral corticosteroids and the risk of serious infections in patients with elderly-onset inflammatory bowel diseases. Am J Gastroenterol 2014;109:1795802.
6. PHAC: Canadian immunization guide - section 3 - Vaccination of specific populations (acquired/secondary immunodeficiency) - http://www.phac-aspc.gc.ca/publicat/cig-gci/p03-07-eng.php#a4 . Accessed July 19 2015. Modified December 5th 2013.
7. PHAC: Canadian Immunization Guide – Section 4 – active vaccines: pneumococcal vaccine - http://www.phac-aspc.gc.ca/publicat/cig-gci/p04-pneu-eng.php#tab1 . Accessed July 19 2015. Modified March 24th 2015.
8. Centers for Disease Control and Prevention (CDC). Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2012;61(40):816.
9. Tomblyn M, Chiller T, Einsele H, at al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transp 2009;15(10):1143.
10. Di Bisceglie AM, Lok AS, Martin P, et al. Recent US Food and Drug Administration warnings on hepatitis B reactivation with immune-suppressing and anticancer drugs: just the tip of the iceberg? Hepatology 2015;61(2):703.
11. Cheng J, Li JB, Sun QL et al. Reactivation of hepatitis B virus after steroid treatment in rheumatic diseases. J Rheumatol 2011;38(1):181–182.
12. Benhamou Y, Bochet M, Thibault V, et al. Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients. Hepatology 1999;30:1302–306.
13. Farthing M, Fedail S, Savioli L, et al. WGO Practice Guideline: Management of Strongyloides. Milwaulkee, WI: Author; 2004.
14. Khan K, Heidebrecht C, Sears J et al. Appendix 8: intestinal parasites – Strongyloides and schistosoma: evidence review for newly arriving immigrants and refugees. CMAJ 2011;183(12):E824–925.
15. Pai M, Kunimoto D, Jamieson F, et al. Canadian Tuberculosis Standards – 7th edition. Centre for Communicable Diseases and Infection Control - Public Health Agency of Canada. February 2014:75.
16. Singh JA, Furst DE, Bharat A, et al. 2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res 2012;64(5):625–39.
17. Liu D, Ahmet A, Ward L, et al. A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy. Allerg Asthma Clin Immunol 2013;9:30.